Point72 Asia (Singapore)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Point72 Asia (Singapore)’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$25.3K	Buy	+3,535	New	+$184K	﹤0.01%	668

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Point72 Asia (Singapore)'s MLTX Position: Q3 2025 in Review

Point72 Asia (Singapore) opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2025: 3,535 shares worth $25.3K. The stake represents ﹤0.01% of the portfolio and ranks #668 among its holdings.

134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

Point72 Asia (Singapore) held 3,535 shares of MoonLake Immunotherapeutics worth $25.3K as of Q3 2025.
MoonLake Immunotherapeutics was a new Point72 Asia (Singapore) position in Q3 2025.
MoonLake Immunotherapeutics made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #668 holding.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.